A researcher at the University of Houston College of Pharmacy has joined a $3.2 million effort to develop a promising new treatment for triple-negative breast cancer (TNBC), one of the most aggressive and difficult-to-treat forms of the disease, accounting for 10-15% of all breast cancer cases.
A groundbreaking development in the treatment of triple-negative breast cancer (TNBC) is emerging from a collaborative research initiative involving the University of Houston and the University of Tennessee Health Science Center.
A groundbreaking development in the treatment of triple-negative breast cancer (TNBC) is emerging from a collaborative research initiative involving the University of Houston and the University of Tennessee Health Science Center.
Research targets deadly triple-negative breast cancer
The Maury Regional Health Care Foundation announced appointments to its board of directors for 2026 during the group’s December meeting.
Liquid biopsies, which test body fluids that contain cancerous material, including circulating tumor DNA (ctDNA), are a noninvasive way to learn about a cancer’s biology.
Liquid biopsies, which test body fluids that contain cancerous material, including circulating tumor DNA (ctDNA), are a noninvasive way to learn about a cancer’s biology.
Memphis researchers are leading the way in learning more about weight loss and cancer.
